Monoclonal Antibodies

Dose 1 for Diabetic Macular Edema

Abilene, TX, Abilene, TX
Targeting 2 different conditionsEYE103Phase 1 & 2RecruitingResearch Sponsored by EyeBiotech Ltd.

Study Summary

This trial tests a potential drug to help people with vision problems caused by diabetes or macular degeneration. It will assess its safety and effectiveness.

Eligible Conditions
  • Diabetic Macular Edema
  • Age-related Macular Degeneration (AMD)

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow ups ~ 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events
Secondary outcome measures
Best-corrected Visual Acuity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

10Treatment groups
Experimental Treatment
Group I: Naïve NVAMD Medium DoseExperimental Treatment1 Intervention
Part 2 Naïve NVAMD combination therapy Medium Dose
Group II: Naïve NVAMD High DoseExperimental Treatment1 Intervention
Part 2 Naïve NVAMD combination therapy High Dose
Group III: Experienced NVAMD Medium DoseExperimental Treatment1 Intervention
Part 2 Experienced NVAMD combination therapy Medium Dose
Group IV: Experienced NVAMD High DoseExperimental Treatment1 Intervention
Part 2 Experienced NVAMD combination therapy High Dose
Group V: Dose 4Experimental Treatment1 Intervention
Part 1 MAD Portion Dose 4 - High Dose
Group VI: Dose 3Experimental Treatment1 Intervention
Part 1 MAD Portion Dose 3 - Mid-High Dose
Group VII: Dose 2Experimental Treatment1 Intervention
Part 1 MAD Portion Dose 2 - Low-Mid Dose
Group VIII: Dose 1Experimental Treatment1 Intervention
Part 1 MAD Portion Dose 1 - Low Dose
Group IX: DME Medium DoseExperimental Treatment1 Intervention
Part 2 Naïve DME monotherapy Medium Dose
Group X: DME High DoseExperimental Treatment1 Intervention
Part 2 Naïve DME monotherapy High Dose

Find a site

Who is running the clinical trial?

EyeBiotech Ltd.Lead Sponsor

Media Library

EYE103 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05919693 — Phase 1 & 2
Diabetic Macular Edema Research Study Groups: Dose 1, Dose 2, Dose 3, Dose 4, DME Medium Dose, DME High Dose, Naïve NVAMD Medium Dose, Naïve NVAMD High Dose, Experienced NVAMD Medium Dose, Experienced NVAMD High Dose
Diabetic Macular Edema Clinical Trial 2023: EYE103 Highlights & Side Effects. Trial Name: NCT05919693 — Phase 1 & 2
EYE103 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05919693 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are partaking in this research endeavor?

"This research requires 92 qualified individuals to participate. Recruitment extends across Lemont, Illinois and Reno, Nevada with sites located in those respective cities."

Answered by AI

Are there any openings for participants in this trial?

"The trial's profile on clinicaltrials.gov affirms that enrolment is still open; the study was initially posted June 12th 2023 and its most recent update occurred two days later, on June 14th of the same year."

Answered by AI

How far-reaching is the availability of this trial?

"This study is currently recruiting patients at 5 distinct sites, such as Lemont in Nevada and Reno in Nevada. Additionally, Germantown located in Tennessee serves as another recruitment centre, with a further five locations also participating."

Answered by AI
~61 spots leftby Dec 2024